Non-selective NSAID

This page covers all Non-selective NSAID drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting COX-1 and COX-2.

Targets

COX-1 and COX-2

Marketed (1)

• Non-selective NSAIDS · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Pain Management, Rheumatology, Cardiovascular
  Non-selective NSAIDs inhibit both COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.